Generic Edurant Availability

Edurant is a brand name of rilpivirine, approved by the FDA in the following formulation(s):

EDURANT (rilpivirine hydrochloride - tablet;oral)

  • Manufacturer: JANSSEN PRODS
    Approval date: May 20, 2011
    Strength(s): EQ 25MG BASE [RLD]

Has a generic version of Edurant been approved?

No. There is currently no therapeutically equivalent version of Edurant available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Edurant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
    Patent 6,838,464
    Issued: January 4, 2005
    Inventor(s): Pease; Elizabeth Janet & Williams; Emma Jane & Bradbury; Robert Hugh & Pearson; Stuart Eric
    Assignee(s): AstraZeneca AB
    Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
    Patent expiration dates:
    • February 26, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
    Patent 7,067,522
    Issued: June 27, 2006
    Inventor(s): Pease; Elizabeth Janet & Williams; Emma Jane & Bradbury; Robert Hugh & Pearson; Stuart Eric
    Assignee(s): AstraZeneca AB
    Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
    Patent expiration dates:
    • December 20, 2019
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • HIV inhibiting pyrimidines derivatives
    Patent 7,125,879
    Issued: October 24, 2006
    Inventor(s): Guillemont; Jérôme Emile Georges & Palandjian; Patrice & de Jonge; Marc René & Koymans; Lucien Maria Henricus & Vinkers; Hendrik Maarten & Daeyaert; Frederik Frans Desiré & Heeres; Jan & Van Aken; Koen Jeanne Alfons & Lewi; Paulus Joannes
    Assignee(s): Janssen Pharmaceutica N.V.
    This invention concerns HIV replication inhibitors of formula (I) the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing −a1=a2−a3=a4—and −b1=b2−b3=b4represents pheynl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl, substituted C1-6alkyl, C1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH?2?, —NHC(═O)R6, —C(═NH)R6 or a 5-membered hetrocycl; X1 is —NR5—, —NH—NH—, —N═N—, —O—, —C(═O)—, C1-4alkanediyl, —CHOH—, —S—, —S(═O)p—, —X2—C1-4alkanediyl- or —C1-4alkanediyl-X2—; R3 is NHR13, NR13R14; —C(═O)—NHR13; —C(═O)—NR13R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; substituted C2-6alkylenyl; C1-6alkyl substituted with hydroxy and a second substituent; —C(═N—O—R8)—C1-4alkyl; R7; or —X3—R7; R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl) amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them
    Patent expiration dates:
    • April 14, 2023
      ✓ 
      Patent use: IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 14, 2023
      ✓ 
      Patent use: IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
    Patent 7,638,522
    Issued: December 29, 2009
    Inventor(s): Guillemont; Jérôme Emile Georges & Stevens; Paul Theodoor Agnes & Copmans; Alex Herman & Peeters; Jozef & Stappers; Alfred Elisabeth & Vandecruys; Roger Petrus Gerebern & Stoffels; Paul
    Assignee(s): Janssen Pharmaceutica N.V.
    The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
    Patent expiration dates:
    • April 14, 2023
      ✓ 
      Drug product
  • HIV inhibiting pyrimidines derivatives
    Patent 8,080,551
    Issued: December 20, 2011
    Inventor(s): Guillemont; Jérôme Emile Georges & Palandijian; Patrice & De Jonge; Marc René & Koymans; Lucien Maria Henricus & Vinkers; Hendrik Maarten & Daeyaert; Frederik Frans Desiré & Heeres; Jan & Van Aken; Koen Jeanne Alfons & Lewi; Paulus Joannes & Janssen;
    Assignee(s): Janssen Pharmaceutica N.V.
    HIV replication inhibitors having formula (I) defined herein are disclosed. Pharmaceutical compositions containing the HIV replication inhibitors; the use of the HIV replication inhibitors in the treatment of HIV; and processes for preparing the HIV replication inhibitors are also disclosed.
    Patent expiration dates:
    • April 11, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
    Patent 8,101,629
    Issued: January 24, 2012
    Inventor(s): Guillemont; Jérôme Emile Georges & Stevens; Paul Theodoor Agnes & Copmans; Alex Herman & Peeters; Jozef & Stappers; Alfred Elisabeth & Vandecruys; Roger Petrus Gerebern & Stoffels; Paul
    Assignee(s): Janssen Pharmaceutica N.V.
    The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
    Patent expiration dates:
    • August 9, 2022
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 20, 2016 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)